An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice

This local, non-interventional, cohort study of patients with metastatic colorectal cancer (mCRC) will prospectively collect data from standard clinical practice of second-line treatment with chemotherapy plus Avastin (bevacizumab). There will be no additional diagnostic or therapeutic procedures required by this study, apart from those performed in everyday clinical practice for second-line treatment of mCRC in Croatia.

Inclusion Criteria:

• Written informed consent
• Age >/=18 years
• Metastatic colorectal cancer (mCRC) previously treated with systemic treatment for advanced disease containing Avastin and chemotherapy; first-line Avastin received according to the Summary of Product Characteristics (SmPC)
• First line progression-free survival (PFS) >6 months
• Eligible for second-line chemotherapy regimen
• Period between first progression and start of second line treatment with Avastin and chemotherapy </=6 weeks

Exclusion Criteria:

• Contraindications, warnings and precautions for use specified in the Avastin SmPC